HLA-A*2402-restricted URLC10-CDCA1-VEGFR1-VEGFR2 multipeptide vaccine

A cancer vaccine containing four HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. The peptide epitopes are derived from URLC10 (up-regulated lung cancer 10); CDCA1 (cell division associated 1); and vascular endothelial growth factor receptors (VEGFRs) 1 and 2. Upon administration, HLA-A*2402-restricted URLC10-CDCA1-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URL10-, CDCA1-, VEGFR1- and VEGFR2-expressing tumor cells, resulting in tumor cell lysis and decreased tumor cell proliferation. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity.